Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2017

01-04-2017 | Original Investigation

Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients

Authors: Abdolvahab Alborzi, Tayebeh Hashempour, Javad Moayedi, Zahra Musavi, Gholamreza Pouladfar, Shahin Merat

Published in: Medical Microbiology and Immunology | Issue 2/2017

Login to get access

Abstract

Interleukin-28B (IL-28B) is suspected to be associated with response to treatment and one of the basic immunological backgrounds in liver transplant candidate (LTC). We aimed to assess whether genotypes of IL-28B can play a role in therapeutic response or advanced stages of liver disease. A total of 364 subjects were genotyped for IL-28B rs12979860 and rs8099917 SNPs using PCR-RFLP assay. Moreover, IL-28 serum level, HCV loads, and genotype were performed. A significant increase was observed in the frequencies of unfavorable rs12979860 genotypes/CT + TT in the chronic hepatitis C (CHC) and LTC groups. In the case of rs8099917, CHC group had a significantly higher frequency of unfavorable genotypes/GT + GG compared to the healthy group. IL-28B serum level was also significantly higher in healthy group compared with the CHC and LTC groups. There were no differences in the distribution of the IL-28B genotypes and haplotypes between responder and non-responder patients. Our results suggest, for the first time, that unfavorable rs12979860 genotypes can be considered one of the important immunological backgrounds in the Iranian LTC population that was confirmed with the lower IL-28 serum level compared to healthy group. Besides, there was a possible association of favorable IL-28B genotypes with lower odds of susceptibility to CHC infection but no support for a positive association between analyzed SNPs and an outcome of therapy. Moreover, non-CT haplotypes may be regarded as a genetic risk factor that can increase the chance of infection with HCV and progression toward end-stage HCV-related liver disease.
Literature
1.
Hashempour T, Bamdad T, Bergamini A, Lavergne JP, Haj-Sheykholeslami A, Brakier-Gingras L et al (2015) F protein increases CD4+CD25+ T cell population in patients with chronic hepatitis C. Pathog Dis 73(4):ftv022CrossRefPubMed
2.
Sarvari J, Moattari A, Pirbonyeh N, Moini M, Hosseini SY (2016) The impact of IFN-γ gene polymorphisms on spontaneous clearance of HCV infection in Fars Province, Southern of Iran. J Clin Lab Anal 30(4):301–307CrossRefPubMed
3.
Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14:e113–e116CrossRefPubMed
4.
Hashempoor T, Bamdad T, Merat S, Janzamin E, Nemati L, Jabbari H et al (2010) Expansion of CD4+CD25+FoxP3+ regulatory T cells in chronic hepatitis C virus infection. Iran J Immunol 7(3):177PubMed
5.
Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T et al (2012) IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 7(5):e37054CrossRefPubMedPubMedCentral
6.
Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R (2009) Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 284(31):20869–20875CrossRefPubMedPubMedCentral
7.
Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA et al (2015) Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015:768470CrossRefPubMedPubMedCentral
8.
Hassan MK, Haq MU, Amin M, Nawaz A, Khan HU (2014) Association between baseline parameters and end of treatment response to combination of conventional interferon and ribavirin in patients with chronic Hepatitis C. J Postgrad Med Inst 28(2):149–153
9.
Aziz H, Raza A, Waheed Y, Gill U, Gill ML (2012) Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients. Int J Infect Dis 16(8):e597–e602CrossRefPubMed
10.
Lin K-H, Yu H-C, Hsu P-I, Tsai W-L, Chen W-C, Lin C-K et al (2013) Baseline high viral load and unfavorable patterns of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy. Hepat Mon 13(10):e11892CrossRefPubMedPubMedCentral
11.
Lai M, Afdhal NH (2012) Clinical utility of interleukin-28B testing in patients with genotype 1. Hepatology 56(1):367–372CrossRefPubMed
12.
Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I et al (2011) Evaluation of prognostic factors for peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 11(3):640–645CrossRefPubMed
13.
Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E et al (2013) Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One 8(8):e72600CrossRefPubMedPubMedCentral
14.
Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS et al (2014) Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. J Gastroenterol Hepatol 29(1):102–109CrossRefPubMed
15.
Ivanova I, Kotsev I, Atanassova M, Atanassova A, Manevska B, Krasnaliev I et al (2013) Baseline viral load-a predictor of treatment response in advanced hepatitis C. Scrip Sci Med 45(3):53–57
16.
Faisal A, Zytoon AA, Allah A-NG, Dawood A (2013) Predictors of early virological response of viral hepatitis C to combination therapy with pegylated interferon plus ribavirin. Am J Clin Med Res 1(4):54–60CrossRef
17.
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL et al (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 43(3):425–433CrossRefPubMed
18.
Sharifi A, Haj-Sheykholeslami A, Poustchi H, Golzari R, Merat S, Malekzadeh R et al (2016) Efficacy of locally manufactured Sofosbuvir and Daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis C and cirrhosis in Iran-preliminary report. Govaresh 21(2):93–97
19.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798–801CrossRefPubMedPubMedCentral
20.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401CrossRefPubMed
21.
Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P et al (2012) Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 93(6):644–649PubMed
22.
Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S et al (2012) Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals. Hepat Mon 12(12):e8387CrossRefPubMedPubMedCentral
23.
Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C et al (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54(3):415–421CrossRefPubMed
24.
Melis R, Fauron C, McMillin G, Lyon E, Shirts B, Hubley LM et al (2011) Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn 13(4):446–451CrossRefPubMedPubMedCentral
25.
He J, Yu G, Li Z, Liang H (2014) Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma. Tumor Biol 35(9):8757–8763CrossRef
26.
Jabari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K et al (2011) Pegaferon in hepatitis C: results of a multicenter study. Middle East J Dig Dis 3(2):110–114
27.
Heidar S, Ali P, Bita B, Maryam K, Leila M, Shima S et al (2012) Development and validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon 2012:190–195
28.
Sullivan S, Jensen D, Bernstein D, Hassanein T, Foster G, Lee S et al (2004) Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 99(8):1490–1496CrossRefPubMed
29.
De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A et al (2014) Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int 2014
30.
Firdaus R, Biswas A, Saha K, Mukherjee A, Chaudhuri S, Chandra A et al (2014) Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One 9(6):e99126CrossRefPubMedPubMedCentral
31.
Khattab MA, Abdelghany HM, Ramzy MM, Khairy RM (2016) Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-α/ribavirin therapy in chronic hepatitis C genotype 4 patients. J Biomed Res 30(1):40CrossRef
32.
Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R et al (2010) Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med 13(4):306PubMed
33.
Moghaddam MA, Zali MR, Andabili SHA, Derakhshan F, Miri SM, Alavian SM (2012) High rate of virological response to Peginterferon α-2a-Ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C. Iran Red Crescent Med J 14(8):466–473
34.
Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J et al (2010) Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52(1):33–37CrossRefPubMed
35.
Akkiz H, Kuran S, Akgöllü E, Usküdar O, Bekar A, Bayram S (2014) The role of Interleukin 28B gene polymorphism in Turkish patients with hepatocellular carcinoma. Ann Hepatol 13:788–795PubMed
36.
Domagalski K, Pawlowska M, Tretyn A, Halota W, Tyczyno M, Kozielewicz D et al (2013) Association of IL28B polymorphisms with the response to peginterferon plus ribavirin combined therapy in Polish patients infected with HCV genotype 1 and 4. Hepat Mon 13(11)
37.
Venegas Santos ME, Villanueva Arancibia RA, González Lagos KV, Brahm Barril JR (2011) IL28B polymorphisms associated with therapy responsee in Chilean chronic hepatitis C patients. World J Gastroenterol 17(31):3636–3639CrossRef
38.
Rashidi R, Toosi MN, Siya RS, Forutan H, Merat S, Daryani NE (2010) The effect of interleukin 28 B polymorphism on sustained virology response (SVR) in patients with chronic hepatitis C. Govaresh 15(3):202–208
39.
Haj-sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F (2015) Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol 21(29):8935CrossRefPubMedPubMedCentral
40.
Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, Henrion J et al (2012) Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and-3 patients. Aliment Pharmacol Ther 36(4):353–362CrossRefPubMed
41.
Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S (2013) Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 11(1):1CrossRef
42.
Chen J, Lin C, Wang C, Lin Y, Kuo S, Shiu C et al (2011) IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 12(4):300–309CrossRefPubMedPubMedCentral
43.
Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M et al (2012) IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol 11(6):876–881PubMed
44.
Wiesmann F, Naeth G, Berger A, Hirsch H, Regenass S, Ross R et al (2016) Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment. Med Microbiol Immunol (Berl) 205(3):263–268CrossRef
45.
Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K (2012) Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Age 19(80.39):0.05
46.
Mach T, Ciesla A, Sanak M, Golwacki M, Warunek W (2012) The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b. Prz Gastroenterol 7:38–42
47.
Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S et al (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54(4):716–722CrossRefPubMed
48.
Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J et al (2013) Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 58(5):969–976CrossRefPubMed
49.
Ren S, Lu J, Du X, Huang Y, Ma L, Huo H et al (2012) Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 61(9):1433–1439CrossRefPubMed
50.
Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y et al (2012) Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One 7(12):e50787CrossRefPubMedPubMedCentral
51.
Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L et al (2012) Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 7(5):e37998CrossRefPubMedPubMedCentral
52.
Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES et al (2013) Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 56(2):84–90CrossRefPubMed
53.
Chiu K-W, Nakano T, Chen K-D, Lin C-C, Hu T-H, Goto S et al (2016) Association of IL28B SNPs rs12979860 and rs8099917 on hepatitis C virus-RNA status in donors/recipients of living donor Liver transplantation. PLoS One 11(6):e0156846CrossRefPubMedPubMedCentral
54.
Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, Morita S et al (2012) Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol 73(3):298–300CrossRefPubMed
55.
Tseng C-W, Chen C-Y, Chang T-T, Tzeng S-J, Hsieh Y-H, Hung T-H et al (2014) Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response. PLoS One 9(6):e100207CrossRefPubMedPubMedCentral
56.
Lin C-C, Wu C-H, Chen H-L, Lin I-T, Wang S-Y, Wang T-E et al (2014) Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection. Ann Hepatol 13(4):350PubMed
57.
Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J et al (2013) Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol 58(6):1104–1112CrossRefPubMed
Metadata
Title
Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients
Authors
Abdolvahab Alborzi
Tayebeh Hashempour
Javad Moayedi
Zahra Musavi
Gholamreza Pouladfar
Shahin Merat
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2017
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-017-0497-y

Other articles of this Issue 2/2017

Medical Microbiology and Immunology 2/2017 Go to the issue

Original Investigation

iTRAQ-based quantitative proteomics reveals important host factors involved in the high pathogenicity of the H5N1 avian influenza virus in mice

Original Investigation

Human polyomavirus and human papillomavirus prevalence and viral load in non-malignant tonsillar tissue and tonsillar carcinoma

Original Investigation

Using dendritic cells to evaluate how Burkholderia cenocepacia clonal isolates from a chronically infected cystic fibrosis patient subvert immune functions

Review

Dysbiosis a risk factor for celiac disease

Rapid Communication

Development of a high-throughput colorimetric Zika virus infection assay

Original Investigation

MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits